1.5 mg semaglutide to tirzepatide vs Semaglutide: Temecula Medical Group: Primary Care Clinic, Direct Primary Care (Concierge Medicine), & Wellness Clinic Switching from Semaglutide to Tirzepatide:

It belongs to the class of GLP-1 receptor agonists, which mimic the natural incretin hormone responsible for regulating blood sugar and appetite. This dual-action effect allows semaglutide to simultaneously improve glycaemic control and promote weight losstwo outcomes that are closely interconnected in metabolic health

For the oral Wegovy tablet, the starting doses (1.5 mg and 4 mg) are available at $149 per month through August 2026, with the 4 mg dose rising to $199 per month after that date

For example, if you inject in the abdomen, choose a different area of the abdomen each time

These compounds support appetite control, glucose metabolism and satiety, pointing to a future where food innovation may target specific dietary needs beyond GLP-1 alone